Immunovant Inc's Customers Performance

Name: Immunovant Inc Customers by Division and Industry - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use

IMVT

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.


IMVT's Source of Revenues		• List of IMVT Customers

for the same period Immunovant Inc

• List of IMVT Customers

Select the Relationship:

Customers ▼

Select the Category:

Comparison ▼

Customers ▼

Basic Report▼

Immunovant Inc's Comment on Sales, Marketing and Customers

News about Immunovant Inc Contracts

Immunovant: Revamping Autoimmune Disease Treatment through Innovative Drug Discovery

Immunovant, Inc. (Nasdaq: IMVT) is a clinical-stage immunology company that strives to improve the lives of individuals suffering from autoimmune diseases. In their recent corporate updates and financial results for the fourth quarter and fiscal year ended March 31, 2024, Immunovant highlighted their commitment to revolutionizing the treatment landscape through their novel drug discovery approach. This article delves into the company s achievements, future prospects, and the potential impact on patients with autoimmune diseases.Advancing Promising Therapies:Immunovant s dedication to discovering effective therapies for autoimmune diseases is evident in their pipeline development. Their leading drug candidate...

Immunovant's IMVT-1402 Sets New Standard in Autoimmune Disease Treatment as a Best-in-Class FcRn Inhibitor

Immunovant s IMVT-1402 Demonstrates Promising Results as a Best-in-Class FcRn Inhibitor
NEW YORK, Nov. 28, 2023 - Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company committed to improving the lives of individuals with autoimmune diseases, has announced positive early findings from the Phase 1 clinical trial of IMVT-1402. These initial results from the 600 mg multiple ascending dose (MAD) cohort indicate the immense potential of IMVT-1402 as a best-in-class neonatal fragment crystallizable receptor (FcRn) inhibitor.
The study, conducted on healthy adults, showcased four subcutaneously administered doses of 600 mg, leading to a mean IgG reduction comparable to that seen with high-dose...

IMVT's Stock Performance relative to it's Customers

IMVT's vs. Customers, Data

(Revenue and Income for Trailing 12 Months, in Millions of $, except Employees)

COMPANY NAME	MARKET CAP	REVENUES	INCOME	EMPLOYEES
Immunovant Inc	8,067.66	0.00	-505.61	207
SUBTOTAL	0.00	0.00	0.00	-

Sources: Immunovant Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: Immunovant Inc’s corporate clients.
For your research, we’ve provided 9 tables on Immunovant Inc corporate clients.
You can find them in the navigation menu under Customers & Markets.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.